Acasti Pharma Inc ACST:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 09/17/21 EDT
2.16quote price arrow down-0.03 (-1.37%)
Volume
3,152
Close
2.19quote price arrow up+0.02 (+0.92%)
Volume
409,897
52 week range
1.37 - 9.76
Loading...
  • Open2.14
  • Day High2.22
  • Day Low2.14
  • Prev Close2.17
  • 52 Week High9.76
  • 52 Week High Date02/10/21
  • 52 Week Low1.37
  • 52 Week Low Date11/06/20

Key Stats

  • Market Cap57.06M
  • Shares Out26.05M
  • 10 Day Average Volume1.23M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-15.77

KEY STATS

  • Open2.14
  • Day High2.22
  • Day Low2.14
  • Prev Close2.17
  • 52 Week High9.76
  • 52 Week High Date02/10/21
  • 52 Week Low1.37
  • 52 Week Low Date11/06/20
  • Market Cap57.06M
  • Shares Out26.05M
  • 10 Day Average Volume1.23M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-15.77

RATIOS/PROFITABILITY

  • EPS (TTM)-1.11
  • P/E (TTM)-1.97
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Acasti Pharma Inc

There is no recent news for this security.

Content From Our Affiliates

Profile

MORE
Acasti Pharma Inc. is a biopharmaceutical company. The Company is focused on the research, development and commercialization of cardiometabolic prescription drugs using omega-3 (OM3) fatty acids delivered both as free fatty acids and bound-to-phospholipid esters, derived from krill oil. Its lead product, CaPre, is an OM3 phospholipid therapeutic. It is developing a cardiovascular drug, CaPre (omega-3 phospholipid) for the treatment of hypertriglyceridemia. CaPre is a krill...
Roderick Carter
Chairman
Janelle D'Alvise
President
Pierre Lemieux Ph.D.
Chief Operating Officer
Brian Ford CPA
Chief Financial Officer
Address
102-3009 boul. de la Concorde E
Laval, QC
H7E 2B5
Canada